AROMASIN NEWS HIGHLIGHTS
Media Articles Related to Aromasin (Exemestane)
Positive Thinking May Protect Against Breast Cancer
Source: Health News from Medical News Today [2008.08.25]
Breast Cancer Phenotypes Linked to Reproductive Factors
Source: MedPageToday.com - Latest medical news and health news plus CME for physicians and healthcare professionals [2008.08.25]
A Sunny Disposition May Protect Against Breast Cancer
Source: MedPage Today Hematology/Oncology [2008.08.21]
Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
Source: Y! Health Bones, Joints & Muscles News [2008.08.21]
Osteo Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
Source: Y! Health Bones, Joints & Muscles News [2008.08.21]
Published Studies Related to Aromasin (Exemestane)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. [2008.04.20]
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. [2008.04.01]
Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat.Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. [2008.03.10]
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT. [2008.03.03]
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. [2007.11]
Clinical Trials Related to Aromasin (Exemestane)
Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane [Active, not recruiting]
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer [Active, not recruiting]
|
